Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”
Year: 2024
Type: letter
Abstract: regarding the role of carvedilol in preventing hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension (CSPH) stratified by a new non-invasive model. 2 Identifying predictors of decompensation in compensated patients is crucial, as the onset of decompensation is closely linked to mortality in cirrhosis.3 The hepatic venous pressure gradient (HVPG) is the gold stan-dard for assessing portal pressure and the foremost predictor of decompensation in cirrhotic patients.4,5 As noted in the editorial, however, the invasive procedure and restricted accessibility of HVPG measurements impede its widespread use.Due to this reason, non-invasive tests are extensively employed to detect CSPH in patients with compensated cirrhosis.The Baveno VII criteria provide specific thresholds for ruling in CSPH if liver stiffness measurement (LSM) ≥25 kPa or out if LSM≤15 kPa plus platelet count (PLT) ≥150×10 9 /L, yet a grey zone exists for patients whose test results fall between these thresholds.6 In such cases, the ANTICI-
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $32
OpenAlex ID: W4402116514